Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Website Naming
-
We have a situation where our brand has 2 indications in 2 different therapeutic areas. We wanted to run with brand.ca but realize that if a patient prescribed the brand for TA #1 is directed to the site, we can't mention the indications for TA #2 as that would link brand to indication for an indication that the patient was not prescribed. We were informed that this is the case when we tried to create an enrolment form that listed indications from 2 different TAs. I was wondering if PAAB has reviewed other brand sites with this situation and how it could be addressed in the URL.
-
Hi @gmc
We have reviewed such sites. In general, the URL for the website (brand.ca) is to the homepage where gating can be started with the DIN number for the patient to enter. Once the patient is in the site, part 3 of the Product Monograph will dictate whether patients can see other therapeutic areas/ indications, i.e. is there only one part 3 for all indications or separate part 3s for separate indications? (we refer you to Section 1.1b of the Guidance on Branded Patient Information). If they are separate part 3's, then one suggestion is for the site to offer an option for the patient to enter their indication in order to enter the appropriate section.